ライフサイエンスコーパス: FDG

1 FDG-PET radiomics features were selected by Lasso-Cox re

2 FDG-PET/CT in patients with SAB seems to improve surviva

3 (18)FDG-PET may enhance the diagnostic efficacy in patients

4 (18)FDG-PET/CT can visualize both inflammation and malignanc

5 Clinic of Samsung Medical Center with an (18)FDG-PET/CT order code were extracted.

6 In contrast, targeted biopsies based on (18)FDG uptake demonstrated a higher diagnostic yield (38.7%

7 emission tomography/computed tomography ((18)FDG-PET/CT) in the differential diagnosis of pericardial

8 18F-FDG PET/CT showed bilateral hypermetabolic adrenal masse

9 18F-FDG-PET/CT accuracy was determined in the subgroups of p

10 The inclusion of abnormal 18F-FDG cardiac uptake as a major criterion at admission ena

11 ccuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single modalities for detecting residual

12 ccuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) for detecting residual disease after neoadj

13 BAT volume and 18F-FDG uptake were not associated with quantified ad libitu

14 Neither BAT volume, nor BAT 18F-FDG uptake after cold stimulation, are related to appeti

15 d after meal consumption nor that of BAT 18F-FDG uptake x time elapsed after meal consumption had any

16 of BAT volume and 18F-fluordeoxyglucose (18F-FDG) uptake after a personalized cold exposure with ener

17 monstrate that pretreatment TRL misleads 18F-FDG-PET/CT during lymph node staging in gynecological ma

18 h node of TRL-positive patients misleads 18F-FDG-PET/CT for detecting nodal metastasis.

19 Use of 18F-FDG-PET/CT at the initial presentation of patients with

20 sitive and negative predictive values of 18F-FDG-PET/CT focal uptake were 93%, 90%, 89%, and 94%, res

21 ere is limited evidence regarding use of 18F-FDG-PET/CT for the diagnosis of native valve endocarditi

22 o present with suspected NVE, the use of 18F-FDG-PET/CT is less accurate and could only be considered

23 gations, we show that the false-positive 18F-FDG-PET/CT result for detecting nodal metastasis can be

24 emission tomography-computed tomography (18F-FDG-PET/CT) can be influenced by the increased glycolyti

25 emission tomography/computed tomography (18F-FDG-PET/CT) has emerged as a useful diagnostic tool for

26 ortionality between glucose metabolism and 2-FDG metabolism, called the lumped constant, or LC.

27 2-Deoxy-2-(18)F-fluoro-d-glucose (2-FDG) with PET is undeniably useful in the clinic, being

28 However, 2-FDG is a good substrate only for facilitated-glucose tra

29 to appreciate the potential limitations of 2-FDG as a surrogate for glucose metabolic rate and the po

30 Given the widespread use of 2-FDG PET to infer glucose metabolism, it is relevant to a

31 Therefore, under these circumstances, the 2-FDG LC used to quantify in vivo glucose utilization shou

32 Even when the readout for the 2-FDG PET study is only an SUV parameter, variability in L

33 ses, to monitor change over time using the 2-FDG SUV metric.

34 tification of glucose metabolic rates with 2-FDG PET, a method that permits the noninvasive assessmen

35 tion chemotherapy with whole-body DW MRI and FDG PET/MRI (alpha = 0.88).

36 therapy response with whole-body DW MRI and FDG PET/MRI in children and young adults.

37 ed agreements between whole-body DW MRI- and FDG PET/MRI-based response classifications with Krippend

38 s who were untreated showed no change in any FDG PET or cardiac MRI parameter.

39 o underwent baseline and response assessment FDG PET-CT between August 2008 and May 2017 were include

40 Correlations between FDG and NaF TBR(max) differed between bifurcations with

41 n the literature on the relationship between FDG uptake and PI.

42 FL and BM FDG uptake lower than the liver background after therapy

43 culprit than in nonculprit atheroma for both FDG (2.08 [0.52] versus 1.89 [0.40]; P<0.001) and NaF (2

44 and volume using [(18)F]fluoro-deoxyglucose (FDG) and simultaneous time-of-flight (TOF) PET/MRI with

45 the studies showed metastases, with diverse FDG PET findings throughout the whole body.

46 (18)F-FDG (12 studies, 171 lesions) showed a pooled sensitivit

47 ray matter regions) SUV difference for (18)F-FDG (3.7% +/- 5.4% for (11)C-UCB-J) compared with HMT, w

48 significantly higher left ventricular (18)F-FDG accumulation in TAC mice than in sham mice on day 3

49 30, 40, 50, 60, 120, and 240 min after (18)F-FDG administration (370 +/- 16 MBq).

50 ese data suggest PET at 2 h after oral (18)F-FDG administration should yield images that are comparab

51 uman biodistribution and dosimetry for (18)F-FDG after oral and intravenous administrations sequentia

52 172H/+); PdxCre) mice were imaged with (18)F-FDG and (111)In-anti-gammaH2AX-TAT.

53 nt of endocrine therapy response using (18)F-FDG and (18)F-fluorofuranylnorprogesterone ((18)F-FFNP)

54 ction and discuss the pros and cons of (18)F-FDG and bacteria-targeting tracers.

55 even lower than that of PET scans with (18)F-FDG and other (18)F tracers; (68)Ga-FAPI-74 is comparabl

56 ial suitability of orally administered (18)F-FDG as an alternative to intravenous administration.

57 tient liver metastases were evident on (18)F-FDG but not on (18)F-FES PET.

58 thorax or abdomen underwent whole-body (18)F-FDG CBM PET/CT using DDG and BG.

59 also compared our detailed intravenous (18)F-FDG dosimetry with older dosimetry data.

60 For (18)F-FDG dynamic studies, COD yielded differences of 3.6% +/-

61 ved a single 3 MBq/kg injected dose of (18)F-FDG followed by a dual-imaging PET scan.

62 sitivity to realistically compete with (18)F-FDG for evaluation of the broad spectrum of malignancies

63 Conclusion: (18)F-FDG has excellent bioavailability after oral administrat

64 The strength of (18)F-FDG has generally been its ability to detect disease in

65 bility to perform whole-body scanning, (18)F-FDG has revolutionized the evaluation of cancer and has

66 e diagnostic performance of whole-body (18)F-FDG imaging using a PET/MRI scanner with time-of-flight

67 aph Vision PET/CT system for oncologic (18)F-FDG imaging, scan duration or activity administration co

68 to activate BAT, volunteers underwent (18)F-FDG imaging.

69 (68)Ga-DOTA-Siglec-9 was comparable to (18)F-FDG in detecting arthritis.

70 d a comparably higher sensitivity than (18)F-FDG in the differentiation between tumor progression and

71 eived a single weight-based (3 MBq/kg) (18)F-FDG injected activity (weight: 45-123 kg [range], 81 +/-

72 in this study, received a weight-based (18)F-FDG injected activity, and underwent list-mode PET acqui

73 Oral (18)F-FDG is a palatable alternative to intravenous (18)F-FDG

74 d use in oncology, the PET radiotracer (18)F-FDG is ineffective for improving early detection of panc

75 dy were to detect differences in brain (18)F-FDG metabolism in CDCS patients with different clinical

76 Blood uptake after orally administered (18)F-FDG peaked at 45-50 min after ingestion.

77 antly higher with immuno-PET than with (18)F-FDG PET (P = 0.009).

78 confidence interval [CI]: 0.72, 0.83); (18)F-FDG PET alone, 0.97 (95% CI: 0.97, 0.98); (18)F-FDG PET/

79 o subregions (i.e., habitats) based on (18)F-FDG PET and contrast CT imaging.

80 f simultaneously obtained quantitative (18)F-FDG PET and diffusion-weighted MRI datasets for predicti

81 templating all subjects with available (18)F-FDG PET and neuropathology information (n = 38), PES of

82 Patients underwent CT and (18)F-FDG PET at baseline and after 4 cycles (the first evalua

83 pproach was established and tested for (18)F-FDG PET brain imaging.

84 Conclusion: FMRI and (18)F-FDG PET capture partly different aspects of network inte

85 (18)F-FDG PET could differentiate G1 and G2 tumors into low- a

86 bjective was to evaluate the impact of (18)F-FDG PET CT on the management of urachal adenocarcinoma (

87 I, 19%-36%) of patients, an additional (18)F-FDG PET exam was requested, because BS provided insuffic

88 showed higher sensitivity than MRI or (18)F-FDG PET for bone lesions (95.8% vs. 90.7% and 89.3%, res

89 ty of radiomic features extracted from (18)F-FDG PET images of cervical tumors.

90 ontrast-enhanced high-resolution CT or (18)F-FDG PET images were used for coregistration.

91 s developed to measure tumor volume in (18)F-FDG PET images.

92 udy evaluating the prognostic value of (18)F-FDG PET imaging and compared it with histologic grading.

93 ts (n = 13) followed by dual MEMRI and (18)F-FDG PET imaging at 10-12 weeks.

94 sess the long-term prognostic value of (18)F-FDG PET imaging for risk stratification of NENs and comp

95 of reduced scan duration in oncologic (18)F-FDG PET imaging on quantitative and subjective imaging p

96 (18)F-FDG PET imaging shows these changes are accompanied by a

97 In assessing response to therapy, (18)F-FDG PET imaging was performed at baseline and 4 d after

98 ws inflammatory leukocyte signal using (18)F-FDG PET imaging.

99 also changed management compared with (18)F-FDG PET in 1 patient (1%; 95% CI, 0%-5%).

100 somewhat higher sensitivity than CT or (18)F-FDG PET in lymph nodes (92.4% vs. 69.7% and 89.4%, respe

101 udy did not support the routine use of (18)F-FDG PET in the general population of NSCLC patients trea

102 (18)F-FDG PET measurement of tumor volume holds promise but is

103 Conclusion: (18)F-FDG PET metabolic volume response predicts survival in p

104 Additional bone lesions on (18)F-FDG PET plus ceCT compared with BS plus ceCT led to chan

105 iplinary expert panel, based on either (18)F-FDG PET plus ceCT or BS plus ceCT.

106 ons based on bone lesion assessment by (18)F-FDG PET plus contrast-enhanced CT (ceCT) or BS plus ceCT

107 s of CT-based criteria with respect to (18)F-FDG PET response criteria in non-small cell lung cancer

108 ated with a shorter OS than a negative (18)F-FDG PET scan (hazard ratio: 3.8; 95% CI: 2.4-5.9; P < 0.

109 whole cohort revealed that a positive (18)F-FDG PET scan was associated with a shorter OS than a neg

110 Brain (18)F-FDG PET showed diffuse cortical hypometabolism associate

111 r risk stratification of NEN patients, (18)F-FDG PET status should be considered.

112 ILC) demonstrates lower conspicuity on (18)F-FDG PET than the more common invasive ductal carcinoma.

113 develop and optimize image metrics for (18)F-FDG PET to assess response to combination docetaxel and

114 elated response criteria (irRC) and on (18)F-FDG PET using PERCIST and immunotherapy-modified PERCIST

115 that 2 radiomic features derived from (18)F-FDG PET were independently associated with local control

116 breast parenchymal uptake (BPU) (from (18)F-FDG PET), mean apparent diffusion coefficient (from diff

117 ts (39% by ceCT, 26% by BS, and 87% by (18)F-FDG PET).

118 tion accuracy was reached by combining (18)F-FDG PET, amyloid PET, and nonimaging variables.

119 le studies suggested that amyloid PET, (18)F-FDG PET, and CSF test combinations may add accuracy to c

120 Amyloid PET, (18)F-FDG PET, and CSF test combinations may add accuracy to c

121 ypical clinical settings, amyloid PET, (18)F-FDG PET, and MRI were highly sensitive for neuropatholog

122 the predictive values of amyloid PET, (18)F-FDG PET, and nonimaging predictors (alone and in combina

123 In multivariate analysis, (18)F-FDG PET, G3 tumor, >=2 liver metastases, and >=2 prior t

124 pendent prognostic factors for OS, and (18)F-FDG PET, G3 tumor, and >=3 liver metastases were indepen

125 aging (MI), championed by radiolabeled (18)F-FDG PET, has expanded the information content derived fr

126 These results were confirmed by (18)F-FDG PET, revealing the least amount of viable tumor tiss

127 sion-weighted early-phase acquisition ((18)F-FDG PET-equivalent), a single scan potentially contains

128 a simultaneous resting-state fMRI and (18)F-FDG PET.

129 resulting in an additional request for (18)F-FDG PET.

130 higher specificity for malignancy than (18)F-FDG PET.

131 18)F-FLT PET/CT was lower than that of (18)F-FDG PET/CT (HDV, 69% [95% CI, 41-89] vs. 94% [95% CI, 70

132 ved the diagnostic value compared with (18)F-FDG PET/CT alone.

133 Conclusion: Qualitative evaluation of (18)F-FDG PET/CT and HRCT perform similarly for the diagnosis

134 ble BAT radiomic features derived from (18)F-FDG PET/CT appear to provide information regarding BAT a

135 (18)F-FDG PET/CT appears to have a limited role in the respons

136 lizumab and had baseline and follow-up (18)F-FDG PET/CT data were analyzed.

137 (18)F-FDG PET/CT detected previously unidentified metastases i

138 Methods: In total, 144 whole-body (18)F-FDG PET/CT examinations were acquired, with a respirator

139 End-of-treatment (EOT) (18)F-FDG PET/CT findings are variable among patients with neg

140 ween different clinical phenotypes and (18)F-FDG PET/CT findings was investigated.

141 (AUCs) for determining hypermetabolic (18)F-FDG PET/CT foci that were suspicious for cancer versus n

142 8)F-FES PET/CT compared favorably with (18)F-FDG PET/CT for detection of metastases in patients with

143 Here, we explore the value of (18)F-FDG PET/CT for guidance of patient management.

144 assessed the diagnostic performance of (18)F-FDG PET/CT for IE and its subtypes.

145 ng both sensitivity and specificity of (18)F-FDG PET/CT for IE.

146 oing role of the more widely available (18)F-FDG PET/CT for response assessment is being recognized t

147 evaluate the diagnostic performance of (18)F-FDG PET/CT for the detection of posttransplantation lymp

148 alue, and negative predictive value of (18)F-FDG PET/CT for the detection of PTLD in children with a

149 ce of high-resolution CT (HRCT) versus (18)F-FDG PET/CT for the diagnosis of pulmonary lymphangitic c

150 Conclusion: (18)F-FDG PET/CT had good specificity and positive predictive

151 Conclusions (18)F-FDG PET/CT had high specificity for all IE subtypes; how

152 a suggest that functional imaging with (18)F-FDG PET/CT has unique merits over anatomic imaging and c

153 Conclusion: Whole-body (18)F-FDG PET/CT identifies the extent of LVAD infection and p

154 atients with lymphoma was segmented on (18)F-FDG PET/CT images (acquired between 2005 and 2011) by a

155 patients with advanced-stage DLCBL and (18)F-FDG PET/CT images available for review were selected.

156 classify uptake patterns of whole-body (18)F-FDG PET/CT images in patients with lung cancer and lymph

157 Results: Twenty-seven patients had (18)F-FDG PET/CT imaging at baseline and after at least 4 cycl

158 ted for uniformity in conjunction with (18)F-FDG PET/CT imaging of mini image-quality phantoms design

159 l cancer underwent baseline and repeat (18)F-FDG PET/CT imaging within 7 d.

160 nal, device-based system for oncologic (18)F-FDG PET/CT imaging.

161 , FAPI PET/CT provides advantages over (18)F-FDG PET/CT in several tumor entities for initial staging

162 e an overview of the current status of (18)F-FDG PET/CT in the monitoring of tumoral and systemic imm

163 for either replacing or complementing (18)F-FDG PET/CT in the selection and monitoring of immunother

164 e suggest adding (18)F-FLT PET/CT when (18)F-FDG PET/CT is inconclusive or positive within the previo

165 The specificity of both CT and (18)F-FDG PET/CT is low because of radiation-induced changes.

166 Although (18)F-FDG PET/CT is widely available and is increasingly being

167 FDG PET/CT, 0.98 (95% CI: 0.97, 0.99); (18)F-FDG PET/CT maximum intensity projection (MIP), 0.98 (95%

168 (MIP), 0.98 (95% CI: 0.98, 0.99); and (18)F-FDG PET/CT MIP atlas, 0.99 (95% CI: 0.98, 1.00).

169 etermine the impact of findings on EOT (18)F-FDG PET/CT on tuberculosis relapse in patients treated w

170 were simultaneously scanned by dynamic (18)F-FDG PET/CT over 60 min, and quantified images were compa

171 Seven of 14 patients with ILC had (18)F-FDG PET/CT performed within 5 wk of the research (18)F-F

172 f PLC, with both being outperformed by (18)F-FDG PET/CT quantitative parameters.

173 (18)F-FDG PET/CT radiomic features are synergistic to visual a

174 s to develop and evaluate a prognostic (18)F-FDG PET/CT radiomic signature in early-stage non-small c

175 Conclusion: A negative EOT (18)F-FDG PET/CT result is protective against tuberculosis rel

176 EPAR I and II studies who underwent an (18)F-FDG PET/CT scan at baseline, a posttreatment (166)Ho SPE

177 ent (166)Ho SPECT/CT scan, and another (18)F-FDG PET/CT scan at the 3-mo follow-up were included for

178 en lymphoma disease) underwent staging (18)F-FDG PET/CT scan.

179 Two of 5 interim (18)F-FDG PET/CT scans and 3 of 9 end-of-treatment (18)F-FDG P

180 recipients who underwent a total of 32 (18)F-FDG PET/CT scans due to clinical suspicion of PTLD withi

181 udy were to assess the value of serial (18)F-FDG PET/CT scans for detecting local recurrence in patie

182 rrying patients received 85 whole-body (18)F-FDG PET/CT scans for the work-up of device infection.

183 Methods: Baseline (18)F-FDG PET/CT scans of 301 DLBCL patients from the REMARC t

184 T/CT scans and 3 of 9 end-of-treatment (18)F-FDG PET/CT scans were false-positive.

185 Twenty-one response assessment (18)F-FDG PET/CT scans were reevaluated according to the Lugan

186 Methods: One hundred forty baseline (18)F-FDG PET/CT scans were selected from U.K. and Dutch studi

187 or these 7 patients, the (18)F-FES and (18)F-FDG PET/CT studies were analyzed to determine the total

188 ance over time, related to advances in (18)F-FDG PET/CT techniques.

189 Our objective was to use (18)F-FDG PET/CT to identify a high-risk subgroup requiring th

190 Conclusion: (18)F-FDG PET/CT was able to identify predictors of survival i

191 Although an abnormal finding on (18)F-FDG PET/CT was added to the 2015 guidelines of the Europ

192 Repeat (18)F-FDG PET/CT was done in patients who relapsed.

193 Adding (18)F-FLT PET/CT when (18)F-FDG PET/CT was positive or inconclusive improved the dia

194 r imaging probes that might complement (18)F-FDG PET/CT will be discussed.

195 ission tomography/computed tomography ((18)F-FDG PET/CT) has recently emerged as another IE imaging m

196 PET alone, 0.97 (95% CI: 0.97, 0.98); (18)F-FDG PET/CT, 0.98 (95% CI: 0.97, 0.99); (18)F-FDG PET/CT

197 on (18)F-FDG PET/CT, Mayo stage after (18)F-FDG PET/CT, and change in patient management were determ

198 tients underwent contrast-enhanced CT, (18)F-FDG PET/CT, and complete peripheral blood sampling at ba

199 Clinical response evaluations included (18)F-FDG PET/CT, endoscopic biopsies, and endoscopic ultrasou

200 e primary malignancy and metastases on (18)F-FDG PET/CT, Mayo stage after (18)F-FDG PET/CT, and chang

201 ts: Of 21 patients with UrC-ADC before (18)F-FDG PET/CT, Mayo staging was I/II in 8, III in 3, and IV

202 Mayo stage before (18)F-FDG PET/CT, rate of detection of the primary malignancy

203 etabolism in the brain, as evaluated by(18)F-FDG PET/CT, seems to correlate with the severe CDCS phen

204 ed 341 patients, of whom 216 underwent (18)F-FDG PET/CT-guided biopsy and 125 underwent CT-guided bio

205 patients diagnosed with lymphoma using (18)F-FDG PET/CT.

206 variables and metabolic parameters by (18)F-FDG PET/CT.

207 the esophagus with an initial staging (18)F-FDG PET/CT.

208 The patients then underwent brain (18)F-FDG PET/CT.

209 irmed STS of the extremities underwent (18)F-FDG PET/MRI before and after ILP with melphalan and tumo

210 ere are differences in multiparametric (18)F-FDG PET/MRI biomarkers of contralateral healthy breast t

211 70 +/- 10 kg) underwent a test-retest (18)F-FDG PET/MRI examination of the brain.

212 with standardized recommendations for (18)F-FDG scanning, and subsequent disease progression influen

213 The (18)F-FDG signal correlated with ejection fraction (r = -0.75,

214 Myocardial MEMRI T(1) correlated with (18)F-FDG standard uptake values and influx constant but not n

215 -operating-characteristic analysis, an (18)F-FDG SUV of more than 2.5 was most accurate to identify s

216 Mean (18)F-FDG uptake and mean (18)F-AV-45 SUV ratio (SUVr) in regi

217 Mean (18)F-FDG uptake and mean (18)F-AV-45 SUVr in AD-typical regio

218 in regional ER estradiol binding, and (18)F-FDG uptake did not show a significant decrease, as would

219 The oral-to-intravenous ratios of (18)F-FDG uptake for major organs at 45 min were 1.07 +/- 0.24

220 f SUL(average) is due to the fact that (18)F-FDG uptake is proportional to tumor volume.

221 (18)F-FDG uptake negatively correlated with pO(2) in the cente

222 Methods: Normalized regional (18)F-FDG uptake of the IC and PAC (reference: cerebellum) was

223 qPET relates residual lymphoma (18)F-FDG uptake to physiologic liver uptake, converting the o

224 o-high ADNC (AUC = 0.72), whereas mean (18)F-FDG uptake was not (AUC = 0.66), although the difference

225 tumor (SUL(total), a measure of total (18)F-FDG uptake), and SUL(average) Results: Baseline TLV rang

226 In contrast to pO(2) and (18)F-FDG uptake, lactate dehydrogenase activity was distribut

227 n AUC of 0.79, 0.88, and 0.90 for mean (18)F-FDG uptake, mean (18)F-AV-45 SUVr, and their combination

228 anually delineated foci with increased (18)F-FDG uptake, specified the anatomic location, and classif

229 On the morning of surgery, (18)F-FDG was injected into the cervix, followed by an immedia

230 a palatable alternative to intravenous (18)F-FDG when venous access is problematic.

231 n the use of (18)F-fluorodeoxyglucose ((18)F-FDG) PET in the assessment of diffuse large B-cell lymph

232 osition, and (18)F-fluorodeoxyglucose ((18)F-FDG) PET, which assesses glucose metabolism, provide val

233 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) combined with co

234 old-standard (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) viability.

235 and (18)F-2-fluoro-2-deoxy-D-glucose ((18)F-FDG) uptake.

236 d did not uptake detectable amounts of (18)F-FDG, compared to control (untreated).

237 layed images, up to 10 half-lives with (18)F-FDG, revealed biologic insight and supported the ability

238 ates are similar to those reported for (18)F-FDG, suggesting that (68)Ga-PSMA-HBED-CC PET/CT may be u

239 maH2AX-TAT, but not (111)In-IgG-TAT or (18)F-FDG, within the pancreas correlated positively with the

240 attern expression scores (PESs) of the (18)F-FDG- and Abeta-ADCRP were compared with Braak tangle sta

241 nation of ADCRPs performed better than (18)F-FDG-ADCRP alone, although there was only negligible impr

242 pathology information (n = 38), PES of (18)F-FDG-ADCRP was a significant predictor of intermediate-to

243 Conclusion: PES of (18)F-FDG-ADCRP, a measure of neurodegeneration, shows close c

244 plorer better delineated the extent of (18)F-FDG-avid disease.

245 There were no patients with (18)F-FDG-avid distant metastases without (18)F-FES-avid dista

246 The most (18)F-FDG-avid lesion according to PERCIST and imPERCIST accur

247 alyzing the SUL(peak) of only the most (18)F-FDG-avid lesion and analyzing up to the 5 most (18)F-FDG

248 d lesions (SUV(max), 2.6-17.9) and 111 (18)F-FDG-avid lesions (SUV(max), 3.3-9.9) suggestive of malig

249 lesion and analyzing up to the 5 most (18)F-FDG-avid lesions.

250 -avid metastases with no corresponding (18)F-FDG-avid metastases.

251 For patients receiving PRRT, (18)F-FDG-negative cases had a significantly longer survival t

252 1), whereas no difference was seen for (18)F-FDG-negative patients.

253 a strong positive correlation between (18)F-FDG-PET and lactate production, while pO(2) was inversel

254 er sequences, in which amyloid-PET and (18)F-FDG-PET are placed at different positions in the order o

255 yglucose positron emission tomography ((18)F-FDG-PET).

256 Herein, we report a (18)F-FDG-PET/CT-based deep learning model, which demonstrates

257 d a significantly longer survival than (18)F-FDG-positive cases, whereas no difference was identified

258 (MTV), and lesion diameter in up to 5 (18)F-FDG-positive lesions per patient.

259 (18)F-FDG-positive patients receiving PRRT had a significantly

260 One-month (18)F-FDG-SUV decreased by 86%; CRR was 63% (95% CI 44-79%).

261 n successfully captured using PET with (18)F-FDG.

262 )Ga-FOL was 20-fold lower than that of (18)F-FDG.

263 was significantly higher than that of (18)F-FDG.

264 and true clinical absorbed doses for [(18)F]FDG and [(18)F]AlF-NOTA-OC were then used to quantify bi

265 ties and differences in the uptake of [(18)F]FDG in dbPET compared to whole-body PET (wbPET) in a coh

266 administration of 186 MBq and 307 MBq [(18)F]FDG on separate days, respectively.

267 Importantly, we show that [(18)F]FDG uptake and cell dry mass have a positive correlation

268 l radiography system and measured the [(18)F]FDG uptake by single HeLa cells together with their dry

269 HeLa cells, which suggests that high [(18)F]FDG uptake in S, G2 or M phases can be largely attribute

270 [(18)F]FDG uptake measurements and 20 radiomic features based o

271 tumor with (18)F-fluorodeoxyglucose ([(18)F]FDG) PET may assist in predicting treatment response in

272 Twelve subjects underwent whole-body [(18)F]FDG-PET/MRI during hyperinsulinemic-euglycemic clamp.

273 easured with fluorine 18 fluorodeoxyglucose (FDG) PET.

274 Radiomics using 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising a

275 ound Fluorine 18 ((18)F)-fluorodeoxyglucose (FDG) PET/CT is a routine tool for staging patients with

276 y investigates (1) (18)F-fluorodeoxyglucose (FDG) and (18)F-sodium fluoride (NaF) uptake in culprit v

277 (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomogra

278 activity (TGA) on [18]F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (P

279 TBR(max) was higher in culprit arteries for FDG (1.92 [0.41] versus 1.71 [0.31]; P<0.001) but not Na

280 he maximum SUV (SUV(max)) is measurable from FDG PET/CT with a within-subject coefficient of variatio

281 In this selected population, all had FDG-avid disease at baseline; by 5-PS, 55 (35%) remained

282 (5-PS), and by calculating percent change in FDG uptake (change in standardized uptake value [DeltaSU

283 e predictive and prognostic value of interim FDG PET (iPET) in evaluating early response to immunoche

284 olling for other risk factors for mortality, FDG-PET/CT performance among all patients was independen

285 Myocardial FDG uptake in patients suspected of having CS is presume

286 Greater lung TGA on FDG PET-CT was associated with worse lung function and r

287 PET.Keywords: digital PET; conventional PET; FDG PET; lesion detection; cancer imaging.

288 Recent studies suggest that FDG-PET/CT could help discriminate between active and re

289 s to provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to

290 1.0% for excluding malignancy based upon the FDG uptake patterns.

291 llin susceptibility and survival duration to FDG-PET/CT.

292 rodeoxyglucose positron emission tomography (FDG-PET) at baseline, after 2 cycles of chemotherapy (in

293 These results suggest that pre-treatment FDG-PET features may be useful to detect patients who do

294 oup) were prospectively recruited to undergo FDG-PET/CT 7-14 days after diagnosis.

295 p of patients with SAB who had not undergone FDG-PET/CT, matched by age, Charlson score, methicillin

296 ilateral carotid stenosis of >=50% underwent FDG-positron-emission tomography and NaF-positron-emissi

297 ective regional genetic effects of voxelwise FDG-positron emission tomography measures between 116 RO

298 concentrated at carotid bifurcations, while FDG was distributed evenly throughout arteries.

299 Methods: Healthy subjects were imaged with FDG on the PennPET Explorer.

300 y among small nodes, when used together with FDG-PET.